HUMAN PLURIPOTENT STEM CELLS

Derivation, differentiation and registry of human pluripotent stem cells. Towards the development of applications in personalized medicine.

9 DECEMBER · ONLINE EVENT

Human Pluripotent Stem Cells training course

This course comprises lectures by specialized trainers from academia and industry in the field of human pluripotent stem cells. The online course is aimed to provide an overview of human pluripotent stem cells biology and differentiation. In this one day event we want to provide a scientific, technological and regulatory perspective for the development of human pluripotent stem cells derivatives for applications in personalized medicine. It will be of particular interest to PhD students and postdoctoral fellows aiming to work or already trained in the field of human pluripotent stem cells.

SCIENTIFIC COMMITTEE:

Nuria Montserrat (IBEC)
Ina Meiser (IBMT Fraunhofer)
Julia Neubauer (IBMT Fraunhofer)

ORGANIZED BY:

WITH THE SUPPORT OF:

Programme:

08:30 – 09:00	Warming up session, introduction of the meeting Nuria Montserrat, Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain. Ina Meiser, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany. Julia Neubauer, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany.
09:00 – 09:35	FAIRification of information and research results: setting standards for human pluripotent stem cell lines and associated data. Andreas Kurtz, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany.
09:40 – 10:10	EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells. Julia C. Neubauer, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany.
10:15 – 10:45	Coffee break
10:45 – 11:20	3D vascularized in vitro tissues for disease modelling, drug development and regenerative medicine. Kristina Haase, EMBL Barcelona, Spain.
11:20 – 12:00	Bioengineering 3D printing to develop a personalized regenerative biological ventricular assist device to provide lasting functional support to damaged hearts. Manuel Mazo, CIMA University of Navarra, Spain.
12:05 – 12:40	Identifying mechanisms relevant for cardiac remodeling and repair. Eva van Rooij, Hubrecth Institute, Utrecht, The Netherlands.
12:40 – 14:00	Lunch break
14:00 – 14:40	Taking Heart Development to the Next Level: from 2D cell culture approaches to Cardioids. Sasha Mendjan, Institute of Molecular Biotechnology (IMBA), Vienna, Austria.
14:45 – 15:20	Bioengineered human heart organoids for the study of cardiac development and congenital heart disease. Aitor Aguirre, Michigan State University, USA.
15:25 – 16:00	Tools to facilitate midbrain organoids for modeling Parkinson’s Disease. Richard Josephson, Thermo Fisher Scientific.
16:00 – 16:30	HiPS-derived cardiomyocytes – A validated model in cardiac safety pharmacology. Ralf Kettenhofen, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany.
16:35 – 17:10	Mohamed Kreir, The Janssen Pharmaceutical Companies of Johnson & Johnson, Mechelen, The Netherlands.
17:10 – 17:30	Closing remarks Nuria Montserrat, Institute for Bioengineering of Catalonia (IBEC), Barcelona, Spain. Ina Meiser, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany. Julia Neubauer, Fraunhofer Institute for Biomedical Engineering (IBMT), Sulzbach, Germany.